NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 195 filers reported holding NEKTAR THERAPEUTICS in Q3 2016. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $66,234,000 | -71.7% | 623,316 | -84.1% | 0.72% | -68.3% |
| Q4 2017 | $234,441,000 | +518.1% | 3,925,670 | +148.4% | 2.28% | +607.1% |
| Q3 2017 | $37,927,000 | +12.1% | 1,580,300 | -8.7% | 0.32% | -12.3% |
| Q2 2017 | $33,841,000 | +217.9% | 1,731,000 | +281.7% | 0.37% | +230.6% |
| Q1 2017 | $10,644,000 | +12.6% | 453,500 | -17.5% | 0.11% | +13.3% |
| Q3 2016 | $9,449,000 | +232.0% | 550,000 | +175.0% | 0.10% | +66.1% |
| Q2 2016 | $2,846,000 | +68.9% | 200,000 | +100.0% | 0.06% | +37.2% |
| Q4 2015 | $1,685,000 | -74.5% | 100,000 | -83.3% | 0.04% | -51.7% |
| Q1 2015 | $6,600,000 | -57.4% | 600,000 | -40.0% | 0.09% | -66.3% |
| Q4 2014 | $15,500,000 | +158.1% | 1,000,000 | +73.9% | 0.26% | +156.3% |
| Q3 2013 | $6,006,000 | – | 575,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |